Entero Therapeutics Inc ENTO
$2.99 $0.15 (5.28%) 1D
Last Updated: Nov 28, 12:00 AM·BE
Pricing for DE stocks is delayed by 24 hours
Open navigation menu
Invest
Invest on your own
We do it for you
Halal tools
Screeners
Your portfolio
Calculators
Shariah
Our certifications
Learn
Education
Get help
Pricing
Company
About Musaffa
Investors
Build with us
Is Entero Therapeutics Inc Stock Halal?
Shariah Compliance Analysis of ENTO Stock
Germany Health Care Nano Cap No. As of September 2026, Entero Therapeutics Inc (ENTO) is classified as NOT HALAL by Musaffa under its AAOIFI-based Shariah screening methodology. Entero Therapeutics Inc does not pass Musaffa's business and financial screening criteria.
Entero Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of non-systemic therapies for the treatment of gastrointestinal diseases. The company is headquartered in Boca Raton, Florida and currently employs 2 full-time employees. The company went IPO on 2016-10-11. The firm is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The firm is focused on developing the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis (CF) and chronic pancreatitis (CP) patients with exocrine pancreatic insufficiency (EPI). Adrulipase is the active pharmaceutical ingredient (API) derived from Yarrowia lipolytica, an aerobic yeast naturally found in various foods such as cheese and olive oil that is widely used as a biocatalyst in several industrial processes. The firm is developing Adrulipase for two principal therapeutic indications: children and adults affected by CF, and adult patients with CP.
ENTO Shariah Compliance
Screening Methodology: AAOIFI
As of September 2026, Entero Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Entero Therapeutics Inc (ENTO) Chart
Financial Metrics & Statements of Entero Therapeutics Inc (ENTO)
FAQ's for Entero Therapeutics Inc (ENTO)
- As of September 2026, Entero Therapeutics Inc ENTO is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Entero Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Entero Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Entero Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Entero Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Entero Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Entero Therapeutics Inc (ENTO)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
